India Pharma Outlook and Latest News – Pharmaceutical Industry in India
India’s pharmaceutical industry is one of the world’s largest, ranking third globally by volume and 14th by value, with a market valued at approximately $60 billion. Known as the “Pharmacy of the World,” India provides around 40% of the generic medicines consumed in the United States and produces more than 50% of the world’s vaccines.
The Indian pharma sector is projected to grow 9–11% in FY2026, driven by strong domestic demand of 8–10% and robust European market expansion of 15–17%, while US growth slows to 4–6% due to price erosion and regulatory challenges. Operating profit margins remain stable at 24–25% supported by favorable raw material costs and rising specialty product share, with R&D spending at 6–7% of revenues focused on complex molecules and innovation. The industry is transitioning from volume-led supply to value-driven global partnerships, moving from “World’s Pharmacy” to “World’s Innovation Partner,” as exports hit a record $30+ billion in FY25 (+9.4% over FY24). With $250 billion worth of innovator drugs going off patent over the next 5 years, significant opportunities exist for generics and complex products, backed by government support of Rs. 5,268 crore for the Department of Pharmaceuticals and GST exemptions on select medicines.
India Pharma Monitor is designed as a centralized platform to track these developments efficiently. It curates key updates across regulatory changes, market trends, export activity, research advancements, and industry movements in a structured format. The aim is to offer readers a clear and reliable overview of the Indian pharmaceutical landscape, enabling quicker insights, easier comparison, and better-informed understanding of the sector.
Latest Pharma News
Follow the latest pharma news from India and the wider pharmaceutical industry. This section highlights major headlines, breaking developments, and important daily updates.
-
'Piramal Pharma Has Cut China Raw Material Dependence to Single Digit'
'Piramal Pharma Has Cut China Raw Material Dependence to Single Digit' TradingView
-
Korea’s First Homegrown Obesity Drug Begins Prescriptions, Challenging Mounjaro on Price
Korea’s First Homegrown Obesity Drug Begins Prescriptions, Challenging Mounjaro on Price Businesskorea
-
Pharmaceutical Industry in Crisis: A Threat to Public Health - Pressenza
Pharmaceutical Industry in Crisis: A Threat to Public Health Pressenza - International Press Agency
-
NPPA Revises Prices of 543 Anti-Cancer Medicine Brands, New Rates From November 9
NPPA Revises Prices of 543 Anti-Cancer Medicine Brands, New Rates From November 9 Kashmir Life
-
Lilly’s retatrutide scores another Phase 3 win, Outperforming Ozempic in head-to-head study
Lilly’s retatrutide scores another Phase 3 win, Outperforming Ozempic in head-to-head study pharma.economictimes.indiatimes.com
Regulatory Updates
Track pharmaceutical regulatory updates, policy changes, and compliance-related news. This section is useful for staying informed about approvals, guidelines, and official announcements.
-
Pharmaceutical Industry in Crisis: A Threat to Public Health - Pressenza
Pharmaceutical Industry in Crisis: A Threat to Public Health Pressenza - International Press Agency
-
APEC regulators converge on drug approvals, but uneven implementation slows gains
APEC regulators converge on drug approvals, but uneven implementation slows gains Bioengineer.org
-
Lilly’s retatrutide scores another Phase 3 win, Outperforming Ozempic in head-to-head study
Lilly’s retatrutide scores another Phase 3 win, Outperforming Ozempic in head-to-head study pharma.economictimes.indiatimes.com
-
DRUGS AND BIOLOGICS—D.N.J.: Drugmaker loses cancer drug patent term extensions after missing statutory filing deadline by one day
DRUGS AND BIOLOGICS—D.N.J.: Drugmaker loses cancer drug patent term extensions after missing statutory filing deadline by one day VitalLaw.com
-
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia The Manila Times
Drug Approvals
Read about new drug approvals, product clearances, and important authorisations. This section covers medicines entering the market and other notable approval milestones.
-
A new GLP-1 telehealth option costs $300 a year—but the medication, safety checks and long-term care still matter
A new GLP-1 telehealth option costs $300 a year—but the medication, safety checks and long-term care still matter Medical Daily
-
NHS Western Isles prescribing weight loss drugs at triple the rate of other health boards
NHS Western Isles prescribing weight loss drugs at triple the rate of other health boards BBC
-
Trump administration will allow pharmacies to make popular peptides
Trump administration will allow pharmacies to make popular peptides NPR
-
The FDA Wants to Pull Its Approval of a Drug. It’s Not So Easy.
The FDA Wants to Pull Its Approval of a Drug. It’s Not So Easy. Undark Magazine
-
Glaxo shares slump amid concerns over its vaccine pipeline of new drugs as patent losses loom
Glaxo shares slump amid concerns over its vaccine pipeline of new drugs as patent losses loom This is Money
Clinical and Research Updates
Explore clinical trial news, research findings, and developments in pharmaceutical science. This section focuses on innovation, studies, and progress in drug development.
-
Claude Makers Acquire 1-Person Biotech Startup
Claude Makers Acquire 1-Person Biotech Startup Trak.in
-
Marijuana and heart disease: A troubling study. Or maybe not.
Marijuana and heart disease: A troubling study. Or maybe not. American Council on Science and Health
-
AI paves the way for bringing medical advancements into practical treatment.
AI paves the way for bringing medical advancements into practical treatment. Vietnam.vn
-
Ono Pharma Announces Results From Five Phase 2 Clinical Studies of ONO-1110, an Endocannabinoid Modulator
Ono Pharma Announces Results From Five Phase 2 Clinical Studies of ONO-1110, an Endocannabinoid Modulator Business Wire
-
Protina, a new drug development company, has accelerated overseas technology transfer by expanding t..
Protina, a new drug development company, has accelerated overseas technology transfer by expanding t.. 매일경제
Industry Events
Discover pharma conferences, exhibitions, seminars, and industry events in India. This section helps readers keep track of sector gatherings and professional events.
-
ARS Pharma to Report Third Quarter 2026 Financial Results
ARS Pharma to Report Third Quarter 2026 Financial Results GlobeNewswire
-
Nigeria Health Watch to Host 2026 Future of Health Conference in Abuja
Nigeria Health Watch to Host 2026 Future of Health Conference in Abuja Head Topics
-
Piramal Pharma Limited Announces Results for Q2 and H1 FY27
Piramal Pharma Limited Announces Results for Q2 and H1 FY27 India's News.Net
-
CPHI India & PMEC India 2026 to connect India’s pharma value chain across ingredients, manufacturing and technology
CPHI India & PMEC India 2026 to connect India’s pharma value chain across ingredients, manufacturing and technology Express Pharma
Company Announcements
View company announcements including results, partnerships, expansions, and strategic updates. This section offers insights into the latest moves by pharma businesses.
-
Big Caring launches IPO valuing Malaysian pharmacy chain at $2 billion
Big Caring launches IPO valuing Malaysian pharmacy chain at $2 billion Reuters
-
Formation Bio Launches $600M Drug Development Fund to Expand Clinical-Stage Pipeline
Formation Bio Launches $600M Drug Development Fund to Expand Clinical-Stage Pipeline citybiz
-
Biogen set up for growth even without M&A but CEO won’t rule it out
Biogen set up for growth even without M&A but CEO won’t rule it out BioSpace
-
Blue Matter ‘turbocharges’ global reach of comms agency Cognite with acquisition
Blue Matter ‘turbocharges’ global reach of comms agency Cognite with acquisition Fierce Pharma
-
Eversana combines forces with UK-based AI health economics research firm Estima in acquisition
Eversana combines forces with UK-based AI health economics research firm Estima in acquisition Fierce Pharma
Market and Sector Headlines
Stay informed on market trends, sector performance, and broader industry headlines. This section gives a wider view of the forces shaping the pharmaceutical market.
-
Biocon named among Science magazine’s best employers in global biotech and pharma for 2026
Biocon named among Science magazine’s best employers in global biotech and pharma for 2026 Business Upturn
-
SciVision Biotech's Drug-Containing Hyaluronic Acid Filler Wins China Class III Medical Device Certificate; Shares Gap Up and Lock at Limit-High NT$43.25
SciVision Biotech's Drug-Containing Hyaluronic Acid Filler Wins China Class III Medical Device Certificate; Shares Gap Up and Lock at Limit-High NT$43.25 BigGo Finance
-
[Opening Market] KOSPI Opens Above 6,000 on Semiconductor Rally
[Opening Market] KOSPI Opens Above 6,000 on Semiconductor Rally Businesskorea
-
Freenome (Nasdaq:FRNM) - Stock Analysis
Freenome (Nasdaq:FRNM) - Stock Analysis Simply Wall St
-
Intellia Therapeutics, Inc. (NTLA) stock price, news, quote and history
Intellia Therapeutics, Inc. (NTLA) stock price, news, quote and history Yahoo Finance UK
Policy and Government Initiatives
This section covers new regulations, industry support measures, and reforms that affect manufacturing, pricing, and compliance. It is also useful for following government schemes that encourage domestic production, exports, and research-led growth.
-
Sensex gains over 150 points, Nifty above 22,730 amid elevated crude oil prices and Fed keeping rates unchanged
Sensex gains over 150 points, Nifty above 22,730 amid elevated crude oil prices and Fed keeping rates unchanged India's News.Net
-
Silver imports surge at India’s bullion exchange after new licensing rules
Silver imports surge at India’s bullion exchange after new licensing rules Livemint
-
Going to China from India? Your visa process has changed. Check these new rules before you apply
Going to China from India? Your visa process has changed. Check these new rules before you apply Business Today
-
Orphan Drug Incentives in 9 APAC Markets, Compared
Orphan Drug Incentives in 9 APAC Markets, Compared BioPharma APAC
-
US Health Secretary Kennedy opens access to some unapproved peptides
US Health Secretary Kennedy opens access to some unapproved peptides Reuters
Get the top pharma headlines every morning
One short email a day with the biggest stories in Indian and global pharma. Free, and you can unsubscribe any time.